Degludec

Type: Product
Name: Degludec
First reported Sep 19 2014 - Updated Sep 19 2014 - 4 reports

Novo Nordisk's Xultophy diabetes combo approved in Europe

Novo Nordisk is preparing to launch Xultophy in its first countries in the European Union in the first half of next year after gaining European Commission approval for the diabetes treatment.Xultophy (formerly known as IDegLira) combines the Danish pharma ... [Published PMLive - Sep 19 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Novo Nordisk's Phase IIIb trial of Ryzodeg fails to meet primary endpoint

Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus ... [Published PBR - News - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 19 2014 - 6 reports

Data shows Novo Nordisk's Ryzodeg provides successful glycaemic control with fewer injections than a basal-bolus regimen

Data presented recently at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than ... [Published PharmaBiz - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 1 reports

Insulin Degludec (Tresiba) Demonstrates Long-Term Efficacy in Children and Adolescents With Type-1 Diabetes

Treatment noninferior to insulin detemirNew clinical data from the BEGIN Young 1 trial have been announced at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD). The trial investigated once-daily insulin degludec (Tresiba, ... [Published PT Community - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

New data show long-term efficacy and safety of Tresiba® in children and adolescents with type 1 diabetes

Vienna, Austria, 16 September - Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba® (insulin degludec) ... [Published Novo Nordisk A/S - Press Releases - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Improved glycaemic control with fixed-ratio combination of insulin degludec and liraglutide

Source: Image Point Fr / Shutterstock.comThe DUAL trial found that rates of hypoglycaemia were lowest with liraglutide, highest with insulin degludec and intermediate with IDegLiraBasal insulin and glucagon-like peptide (GLP)-1 receptor agonists are individually ... [Published Pharmaceutical Journal - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

'Most Powerful' Combo for Type 2 Diabetes Fulfils Promise

New research published in The Lancet suggests that a combination of an injectable glucagonlike peptide-1 (GLP-1) agonist with basal insulin may be an excellent treatment option in patients with type 2 diabetes, resulting in robust blood glucose control ... [Published General Medicine eJournal - Sep 12 2014]
Entities: GLP-1, agonist, Insulin
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Novo Nordisk launches diabetes drug in Mexico

Novo Nordisk, a provider of pharmaceutical products and services, has launched Ryzodeg, a combination of two insulin analogues for the treatment of type 2 diabetes, in Mexico. Ryzodeg is a combination of two distinct insulin analogues (insulin degludec ... [Published Individual.com - Sep 10 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Novo Nordisk quits inflammation R&D and cuts jobs

Novo Nordisk is terminating its inflammatory disease R&D programmes after the company’s leading rheumatoid arthritis drug candidate failed in clinical trials. The move means 400 jobs will be cut, but the Danish diabetes specialist expects to be able to ... [Published RSC - Sep 04 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Data shows that IDegLira improves glycaemic control in type 2 diabetes

The Lancet & Endocrinology has published the phase 3a DUALTM I study investigating IDegLira (; Xultophy®) once-daily, single injection insulin degludec (Tresiba®) and liraglutide (Victoza®).The results show that people with taking IDegLira have a significantly ... [Published Hospital Pharmacy Europe - Sep 04 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 2 reports

Novo Nordisk gives up on inflammation R

The failure of Novo Nordisk's phase II data trial of NN826 in rheumatoid arthritis has had far-reaching consequences, with the company opting to pull out of inflammation R&D altogether.Last month, Novo Nordisk reported that it had decided to discontinue ... [Published PMLive - Sep 03 2014]
First reported Sep 01 2014 - Updated Sep 02 2014 - 6 reports

Novo Nordisk debuts diabetes combo in Mexico

Danish pharma company Novo Nordisk has not had the best of times with its diabetes pipeline of late, but chalked up a success with the first launch of its Ryzodeg combination insulin product in Mexico.Ryzodeg combines the long-acting basal insulin in ... [Published PMLive - Sep 02 2014]

Quotes

...The company's chief scientific officer Mads Krogsgaard Thomsen said the treatment "represents a new paradigm with the potential to transform how type 2 diabetes is treated" . Xultophy was granted approval in Switzerland last week and Novo expects to launch in the first European Union nations in the first half of next yea...
...ypoglycaemia compared to basal-bolus regimens," said Dr Helena Rodbard, the study's principal investigator and endocrinologist in Rockville MD, USA. "This new treatment offers the potential for a simple alternative to basal-bolus for patients who require intensification of basal insulin regimens" she added
"We believe that Xultophy represents a new paradigm with the potential to transform how type 2 diabetes is treated. We look forward to making the product available to people with type 2 diabetes in Europe" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk
"When treating children and adolescents with type 1 diabetes, it is critical that the right balance between glycemic control and side effecteffect management is maintained to ensure the best possible long-term outcomes,” noted Nandu Thalange, MD, a pediatric endocrinologist at Norfolk and Norwich University Hospital in the United Kingdom. “These data show that Tresiba has the potential to offer youngsters with diabetes a new treatment option, which may help them achieve better control of their diabetes.”"

More Content

All (54) | News (43) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Novo Nordisk’s Tresiba Shows Efficacy In Childr... [Published Bioresearch Online - Sep 19 2014]
Novo Nordisk's Xultophy diabetes combo approved... [Published PMLive - Sep 19 2014]
Novo Nordisk's Phase IIIb trial of Ryzodeg fail... [Published PBR - News - Sep 19 2014]
New Xultophy® (IDegLira) data show rapid and pr... [Published Noodls - Sep 19 2014]
Novo Nordisk granted EU approval for combo diab... [Published Zenopa - Sep 19 2014]
Data shows Novo Nordisk's Ryzodeg provides succ... [Published PharmaBiz - Sep 19 2014]
EC Approves Xultophy for Adult Diabetes [Published Drug Discovery and Development - Sep 19 2014]
Europe okays Novo Nordisk diabetes combo Xultophy [Published Pharma Times - Sep 19 2014]
Ryzodeg Offers Glycemic Control With Fewer Inje... [Published Drug Discovery and Development - Sep 18 2014]
Tresiba Insulin Improves Glycemic Control in Ch... [Published Pharmacy Times - Sep 18 2014]
Novo Nordisk A/S's Diabetes Drug Ryzodeg Effect... [Published BioSpace - Sep 18 2014]
Novo's Ryzodeg provides glycemic control with f... [Published Seeking Alpha - Sep 18 2014]
Ryzodeg® provides successful glycaemic control ... [Published Noodls - Sep 18 2014]
Ryzodeg® provides successful glycaemic control ... [Published Novo Nordisk A/S - Press Releases - Sep 18 2014]
Insulin Degludec (Tresiba) Demonstrates Long-Te... [Published PT Community - Sep 17 2014]
Novo's New Diabetes Drug Effective and Safe for... [Published American Journal of Public Health - Sep 17 2014]
New data show long-term efficacy and safety of ... [Published Novo Nordisk A/S - Press Releases - Sep 16 2014]
Insulin with GLP-1 combo drug more effective ei... [Published Diabetes.co.uk - Sep 15 2014]
Long live peptides evolution of peptide half-li... [Published Drug Discovery World - Sep 15 2014]
Improved glycaemic control with fixed-ratio com... [Published Pharmaceutical Journal - Sep 15 2014]
'Most Powerful' Combo for Type 2 Diabetes Fulfi... [Published General Medicine eJournal - Sep 12 2014]
Lantus faces first biosimilar rival in Europe [Published PMLive - Sep 11 2014]
Liraglutide seems effective in obesity, says FD... [Published PMLive - Sep 11 2014]
Novo Nordisk launches diabetes drug in Mexico [Published Individual.com - Sep 10 2014]
Lilly says peglispro tops Lantus in diabetes tr... [Published PMLive - Sep 05 2014]
Novo Nordisk Discontinues Inflammatory Disease ... [Published Bioresearch Online - Sep 04 2014]
Novo Nordisk quits inflammation R&D and cuts jobs [Published RSC - Sep 04 2014]
Data shows that IDegLira improves glycaemic con... [Published Hospital Pharmacy Europe - Sep 04 2014]
Novo Nordisk gives up on inflammation R [Published PMLive - Sep 03 2014]
Novo Nordisk introduces Ryzodeg in Mexico for t... [Published Pharmaceutical Technology - Sep 02 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Novo Nordisk's Phase IIIb trial of Ryzodeg fail... [Published PBR - News - Sep 19 2014]
Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus ...
Ryzodeg® provides successful glycaemic control ... [Published Novo Nordisk A/S - Press Releases - Sep 18 2014]
Vienna, Austria, Thursday 18 September 2014 - Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg® (insulin degludec/insulin aspart) administered twice daily, provides successful ...
New data show long-term efficacy and safety of ... [Published Novo Nordisk A/S - Press Releases - Sep 16 2014]
Vienna, Austria, 16 September - Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba® (insulin degludec) ...
Mexico first country to launch Ryzodeg® [Published Novo Nordisk A/S - Press Releases - Sep 01 2014]
Bagsværd, Denmark, 1 September 2014 - Novo Nordisk today announced that in Mexico, as the first country in the world, Ryzodeg® is now launched and made available for people with type 2 diabetes. Ryzodeg® is a combination of two distinct insulin analogues ...
Novo Nordisk's Insulin Degludec/Liraglutide is ... [Published PR Newswire: General Business - Jul 07 2014]
BURLINGTON, Mass., July 7, 2014 /PRNewswire/ -- Decision Resources Group finds that Novo Nordisk's fixed-dose combination (FDC) therapy insulin degludec/liraglutide (Xultophy, formerly known as IDegLira) is set to become the clinical gold-standard ...
1 2

Press Releases

sort by: Date | Relevance
Novo Nordisk A/S: Novo Nordisk receives positiv... [Published GlobeNewswire: Acquisitions News - Jul 25 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.